This newslink doesn't exist or it was removed.
Go to Homempage.
MarketWatch USA Business September 25, 2023
But the study, which was conducted by a team of mostly U.K.-based academics, found that in some patients, molnupiravir did not succeed in killing the virus but instead allowed the mutated virus to spread. “Using a systematic approach, we find that a specific class of long... + más
Merck Tops Quarterly Profit Estimates but Sees Weaker 2023 Revenue on Lagevrio Sales Drop | MarketWatch
Are COVID drugs creating super viruses? Scientists weigh in | Newsweek
Forbes USA Tech February 03, 2023
Sign warning of thin ice.getty This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the level of the individual, , and for an overview of the risks on a societal level, . Mutations to the SARS-CoV-2 genome, especially in the spike... + más
As COVID-19 Ravages China, Some Seek Black Market Drugs | Time
The best treatment for COVID-19 could be the one you can’t get | The Boston Globe
MarketWatch USA Business May 18, 2023
Teva’s ADR jumped 7.3% on Thursday morning, as investors awaited an investor day presentation scheduled to start at 12 p.m. Eastern. The drugmaker has been struggling since a series of ill-advised acquisitions a decade ago, notably the decision to buy Actavis Generics for... + más
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis | ABC News
What Are the Duties of A Trustee? | Forbes
MarketWatch USA Business February 02, 2023
The company is expecting revenue to drop in 2023 amid a decline in sales of Lagevrio, its Covid-19 antiviral, and on Thursday set earnings guidance that was well below Wall Street expectations. Still, Merck Chief Financial Officer Caroline Litchfield said that the company’s... + más
Merck, Moderna detail potential skin cancer vaccine progress | WPLG Local 10
Merck, Moderna detail potential skin cancer vaccine progress | ABC News
Portland Press Herald USA World June 06, 2023
This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. AP Photo/Seth Wenig, File Merck is suing the U.S. over a law that will allow the government to negotiate prescription-drug prices with pharmaceutical companies — a reform aimed at cutting costs... + más
European committee: Regulators should deny Merck's Lagevrio | Associated Press
About iurex | Privacy Policy | Disclaimer |